<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03207399</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00074361</org_study_id>
    <nct_id>NCT03207399</nct_id>
  </id_info>
  <brief_title>Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment</brief_title>
  <official_title>Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment: A Pilot Feasibility and Efficacy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether treatment with Epclusa
      (sofosbuvir/velpatasvir) after lung transplantation in individuals with chronic hepatitis C
      infection is feasible, safe and effective at curing HCV.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment terminated due to not having any other eligible participants.
  </why_stopped>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Actual">March 25, 2019</completion_date>
  <primary_completion_date type="Actual">March 25, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Sustained Virologic Response 12 Weeks (SVR 12) in Those Treated With EPCLUSA.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Sustained Virologic Response 12 weeks (SVR 12) in those treated with EPCLUSA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients That Reported an Adverse Event Resulting in Discontinuation of EPCLUSA</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events resulting in discontinuation of EPCLUSA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Eligible for EPCLUSA Treatment</measure>
    <time_frame>within 12 months of lung transplant</time_frame>
    <description>Eligibility for EPCLUSA treatment within 12 months of lung transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum HCV RNA Levels</measure>
    <time_frame>12, 24, and 48 weeks after initiation of EPCLUSA</time_frame>
    <description>Serum HCV RNA levels at 12-, 24-, and 48-weeks after initiation of EPCLUSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Requiring Temporary Interruption of EPCLUSA Therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events requiring temporary interruption in EPCLUSA therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>90 days post-transplant</time_frame>
    <description>90-day post transplant patient survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>1 year post-tranplant</time_frame>
    <description>1 year post transplant patient survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>90 days post-transplant</time_frame>
    <description>90-day post transplant patient survival in recipients of HCV NAT positive donor organ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>1 year post transplant patient survival in recipients of HCV NAT positive donor organ</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Lung Transplant</condition>
  <arm_group>
    <arm_group_label>Epclusa</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epclusa</intervention_name>
    <description>Patients will be treated with this drug for 12 weeks post lung transplant.</description>
    <arm_group_label>Epclusa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV RNA &gt;= 10^3 IU/ml at screening

          -  Chronic HCV infection, defined as positive HCV antibody and/or HCV RNA more than 6
             months prior to screening

          -  HCV Genotype 1, 2, 3, 4, 5 or 6

          -  Otherwise eligible for lung transplant at study site

        Exclusion Criteria:

          -  Age &lt;18

          -  Treatment with any of the following agents:

               -  Amiodarone. Subjects previously treated with amiodarone must have stopped the
                  amiodarone at least 60 days prior to day 1 SOF/VEL

               -  Carbamazepine, phenytoin, phenobarbital, oxcarbazepine

               -  Rifabutin, rifampin or rifapentine

               -  HIV regimens containing tenofovir or tipranavir/ritonavir

               -  St John's wort

               -  PPIs, including: Omeprazole, pantoprazole, esomeprazole, lansoprazole,
                  dexlansoprazole, rabeprazole

               -  Modafinil

          -  Have any serious or active medical or psychiatric illness which, in the opinion of the
             investigator, would interfere with subject treatment, assessment or compliance

          -  Hepatitis B surface antigen positive

          -  History of hepatic encephalopathy or variceal hemorrhage

          -  Abnormal hematological and biochemical parameters, including:

               -  Hemoglobin &lt;8g/dL

               -  Platelets &lt;= 50,000/mm^3

               -  ALT (alanine aminotransferase), AST (aspartase aminotransferase) or alkaline
                  phosphatase &gt;=10 times ULN

               -  Total bilirubin &gt;3mg/dL

               -  Severe renal impairment, ie creatinine clearance (CrCl) &lt;30mL/min

          -  Pregnant women or women planning to become pregnant

          -  Women or are breastfeeding

          -  Active or recent history (&lt;=1 year) of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Mohamedaly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Heath</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <results_first_submitted>June 3, 2019</results_first_submitted>
  <results_first_submitted_qc>August 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 11, 2019</results_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03207399/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03207399/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Epclusa</title>
          <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
Epclusa: Patients will be treated with this drug for 12 weeks post lung transplant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Epclusa</title>
          <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
Epclusa: Patients will be treated with this drug for 12 weeks post lung transplant.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sustained Virologic Response 12 Weeks (SVR 12) in Those Treated With EPCLUSA.</title>
        <description>Sustained Virologic Response 12 weeks (SVR 12) in those treated with EPCLUSA.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epclusa</title>
            <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
Epclusa: Patients will be treated with this drug for 12 weeks post lung transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Virologic Response 12 Weeks (SVR 12) in Those Treated With EPCLUSA.</title>
          <description>Sustained Virologic Response 12 weeks (SVR 12) in those treated with EPCLUSA.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients That Reported an Adverse Event Resulting in Discontinuation of EPCLUSA</title>
        <description>Adverse events resulting in discontinuation of EPCLUSA</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epclusa</title>
            <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
Epclusa: Patients will be treated with this drug for 12 weeks post lung transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Reported an Adverse Event Resulting in Discontinuation of EPCLUSA</title>
          <description>Adverse events resulting in discontinuation of EPCLUSA</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Eligible for EPCLUSA Treatment</title>
        <description>Eligibility for EPCLUSA treatment within 12 months of lung transplant</description>
        <time_frame>within 12 months of lung transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epclusa</title>
            <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
Epclusa: Patients will be treated with this drug for 12 weeks post lung transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Eligible for EPCLUSA Treatment</title>
          <description>Eligibility for EPCLUSA treatment within 12 months of lung transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum HCV RNA Levels</title>
        <description>Serum HCV RNA levels at 12-, 24-, and 48-weeks after initiation of EPCLUSA</description>
        <time_frame>12, 24, and 48 weeks after initiation of EPCLUSA</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epclusa</title>
            <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
Epclusa: Patients will be treated with this drug for 12 weeks post lung transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum HCV RNA Levels</title>
          <description>Serum HCV RNA levels at 12-, 24-, and 48-weeks after initiation of EPCLUSA</description>
          <units>IU/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">HCV RNA value fell below the level of detection.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">HCV RNA value fell below the level of detection.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">HCV RNA value fell below the level of detection.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Requiring Temporary Interruption of EPCLUSA Therapy</title>
        <description>Adverse events requiring temporary interruption in EPCLUSA therapy</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epclusa</title>
            <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
Epclusa: Patients will be treated with this drug for 12 weeks post lung transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Requiring Temporary Interruption of EPCLUSA Therapy</title>
          <description>Adverse events requiring temporary interruption in EPCLUSA therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Survival</title>
        <description>90-day post transplant patient survival</description>
        <time_frame>90 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epclusa</title>
            <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
Epclusa: Patients will be treated with this drug for 12 weeks post lung transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival</title>
          <description>90-day post transplant patient survival</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Survival</title>
        <description>1 year post transplant patient survival</description>
        <time_frame>1 year post-tranplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epclusa</title>
            <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
Epclusa: Patients will be treated with this drug for 12 weeks post lung transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival</title>
          <description>1 year post transplant patient survival</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Survival</title>
        <description>90-day post transplant patient survival in recipients of HCV NAT positive donor organ</description>
        <time_frame>90 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epclusa</title>
            <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
Epclusa: Patients will be treated with this drug for 12 weeks post lung transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival</title>
          <description>90-day post transplant patient survival in recipients of HCV NAT positive donor organ</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Survival</title>
        <description>1 year post transplant patient survival in recipients of HCV NAT positive donor organ</description>
        <time_frame>1 year post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epclusa</title>
            <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
Epclusa: Patients will be treated with this drug for 12 weeks post lung transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival</title>
          <description>1 year post transplant patient survival in recipients of HCV NAT positive donor organ</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>11 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Epclusa</title>
          <description>Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
Epclusa: Patients will be treated with this drug for 12 weeks post lung transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment in the clinical trial did not reach the target number of subjects needed to achieve target power and was insufficient to produce statistically reliable results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Omar Mohamedaly</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-4589</phone>
      <email>omar.mohamedaly@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

